Aaron Cowen’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$229K Buy
+1,010
New +$180K ﹤0.01% 95
2026
Q1
Sell
-1,010
Closed -$201K 93
2025
Q4
$201K Buy
+1,010
New +$183K ﹤0.01% 93
2024
Q3
Sell
-1,010
Closed -$209K 101
2024
Q2
$209K Hold
1,010
0.01% 97
2024
Q1
$274K Hold
1,010
0.01% 101
2023
Q4
$239K Buy
+1,010
New +$199K 0.01% 87
2023
Q3
Sell
-1,010
Closed -$212K 92
2023
Q2
$212K Hold
1,010
0.01% 98
2023
Q1
$204K Hold
1,010
0.01% 93
2022
Q4
$220K Buy
+1,010
New +$221K 0.01% 86

Other funds holding CRL

Aaron Cowen's CRL Position: Q2 2026 in Review

Aaron Cowen opened a new position in Charles River Laboratories (CRL) in Q2 2026: 1,010 shares worth $229K. The stake represents ﹤0.01% of the portfolio and ranks #95 among its holdings. This is a return to the name: Aaron Cowen previously reported a position in CRL as recently as Q4 2025.

Aaron Cowen first reported a position in CRL in Q4 2022 and has held it in 8 quarters since. The position peaked at $274K in Q1 2024. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Aaron Cowen held 1,010 shares of Charles River Laboratories worth $229K as of Q2 2026.
  • Charles River Laboratories was a new Aaron Cowen position in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Aaron Cowen's portfolio in Q2 2026, its #95 holding.
  • Aaron Cowen first reported a position in Charles River Laboratories in Q4 2022 and has held it in 8 quarters since.
  • Aaron Cowen's Charles River Laboratories position peaked at $274K in Q1 2024.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.